"I share the optimism that we have solutions for next year. The challenge here is to get to the scale," GSK CEO Emma Walmsley said at a CBI online event on Tuesday.
Frankfurt:
The CEO of GlaxoSmithKline, the world's largest vaccine maker, said she is optimistic that the industry will be able to make immunization against COVID-19 widely available next year.
GlaxoSmithKline is contributing adjuvants, efficacy enhancers that play a vital role in many vaccines, to several potential future vaccine development alliances against the new coronavirus that has killed more than a million people globally.
The group's most advanced project is with French partner Sanofi, and the two say they hope to secure approval for their candidate next year.
Walmsley stressed that the industry's unprecedented speed in developing vaccination does not harm safety because the trials were not smaller than usual and regulators and companies are taking parallel steps that were previously done in a row.
“We are ramping up timelines that can take 10 years to two years,” the CEO said. “But people should feel very reassured that the way we do it is (because) a completely different level of collaboration with the regulators.”
0 Comments